Oruka Therapeutics, Inc. (ORKA) · Oct 26, 2026 · Other events
Above the bar — PASI 100 61% vs 0% placebo; p<0.0001
Oruka’s Phase 2 psoriasis data validate ORKA-001 across two trials, supporting Phase 3 while annual dosing remains unproven.
Oruka is a clinical-stage biotech trying to turn ultra-long-acting antibodies into psoriasis treatments dosed once or twice a year; ORKA-001 is its lead IL-23p19 program, while ORKA-002 is the other major dermatology program.
The efficacy result clears the trial’s bar decisively. The Phase 2b EVERLAST-B study met its primary endpoint, with 61% of patients on the 600 mg dose reaching complete skin clearance at Week 16 versus 0% on placebo, with p<0.0001. 〔0〕 (Efficacy results — EVERLAST-B) The 86% PASI 90 rate and 86% IGA 0/1 rate reinforce that the result was not dependent on a single unusually strict endpoint. (Exhibit 99.1, Efficacy results)
| Measure | ORKA-001 600 mg | Placebo | Comparison |
|---|---|---|---|
| PASI 100 at Week 16 | 61% | 0% | Primary endpoint; p<0.0001 (Efficacy results — EVERLAST-B) |
| PASI 90 at Week 16 | 86% | Not stated in release | Secondary endpoint (Efficacy results — EVERLAST-B) |
| IGA 0/1 at Week 16 | 86% | Not stated in release | Secondary endpoint (Efficacy results — EVERLAST-B) |
| At least one TEAE | 39% | 43% | Comparable overall event rate (Safety results — EVERLAST-B) |
| Serious TEAEs | 0% | Not stated in release | None in the high-dose group (Safety results — EVERLAST-B) |
The important upgrade is replication, not just another favorable percentage. EVERLAST-B was a larger, global Phase 2b trial with 187 patients and less than 30% site overlap with EVERLAST-A, yet the high-dose response was broadly consistent with the earlier study. 〔1〕 (Trial design — EVERLAST-B) That makes the program’s efficacy signal more credible and gives Oruka a basis to select 600 mg for Phase 3, although the company’s comparisons with approved IL-23 drugs remain cross-trial rather than head-to-head. (Presentation, slides 8, 11-12, 17)
Safety supports advancement but does not yet prove the commercial dosing promise. The high-dose group had fewer reported treatment-emergent adverse events than placebo, no serious TEAEs, and no injection-site reactions. 〔2〕 〔3〕 (Safety results — EVERLAST-B) However, the central value proposition—durable clearance with annual or semiannual dosing—still depends on longer-term maintenance data, not this Week 16 induction readout.
The filing advances Oruka from proof-of-concept toward execution. Management plans to discuss Phase 3 with regulators and start Phase 3 psoriasis trials in the first half of 2027 using the 600 mg dose, subject to those discussions. 〔4〕 (Development plans) The stated $1.1 billion cash position is intended to fund operations through an anticipated ORKA-001 BLA filing and continued ORKA-002 development, reducing the immediate need for financing to advance this program. (Cash Position)
Bottom line: EVERLAST-B materially strengthens the ORKA-001 story by independently reproducing a striking efficacy signal and selecting the Phase 3 dose. The remaining proof point is durability: whether the unusually strong Week 16 clearance persists with once-yearly or twice-yearly dosing.
52-week EVERLAST-A data, December 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!